Finasteride 1.2mg + Minoxidil 3mg daily oral tablet, 3 month progress
    Progress Pictures 7/3/2025

    From the encyclopedia
    Finasteride β†’

    Frontline, gold standard treatment for combatting androgenic alopecia

    Minoxidil β†’

    An essential vasodilator with some anti-androgenic effects

    Biotin β†’

    supplement to help with hair texture and quality

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    πŸ’Š Finasteride (oral) 1.2mg daily 3 months
    πŸ’Š Minoxidil (oral) 3mg daily 3 months
    πŸ’Š Vitamins (oral) daily 3 months
    πŸ’Š Biotin (oral) daily 3 months
    the tone is πŸ˜€ positive with significant hair improvement results.

    Other terms

    The user experienced significant hair improvement after 3 months using daily oral tablets of 1.2mg finasteride and 3mg minoxidil, along with vitamins and biotin. The hairline looks much better despite initial shedding.
    View this post in the Community β†’

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      Hair Loss in Women: Comprehensive Overview and Treatment Options

      research Hair Loss in Women

      81 citations , March 2009 in “Seminars in Cutaneous Medicine and Surgery”
      This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.
      Hair Loss in Men and Women: Medical and Surgical Treatments for Androgenic Alopecia

      research Hair Loss in Men and Women

      April 2019 in “Advances in Cosmetic Surgery”
      The document concludes that ongoing medical therapy is crucial for preventing hair loss, and surgical options can restore hair, with future treatments for hair loss being promising.
      Common Dermatologic Conditions

      research Common Dermatologic Conditions

      14 citations , April 2014 in “Medical Clinics of North America”
      This review discusses common skin conditions in primary care settings and provides guidance on differential diagnoses and selecting appropriate topical treatments, but it reports no new clinical results.